MedTrace Logo

Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer

NCT00308178 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2013-02-18

No results posted yet for this study

Summary

The purpose of this trial is to see if Abraxane, which is a new form of paclitaxel, is safe as a replacement form of paclitaxel in dose-dense chemotherapy. This trial will also determine if using Abraxane will allow patients to receive treatment every two weeks without requiring injects of G-CSF, a white blood cell stimulating growth factor.

Conditions

Interventions

DRUG

Abraxane

Following 4 cycles (8 weeks) of adjuvant chemotherapy (adriamycin and cytoxan), abraxane will be give every 2 weeks for 4 cycles(8 weeks)

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • Beth Israel Deaconess Medical Center

    collaborator OTHER

  • Massachusetts General Hospital

    collaborator OTHER

  • Harold J. Burstein, MD, PhD

    lead OTHER

Principal Investigators

  • Harold Burstein, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2006-09-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00308178 on ClinicalTrials.gov